SCHEMBL8008577

SCHEMBL8008577

Cc1cc(C=O)cc(C(C)(C)C)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 1/20 0.40
RXRB P28702 1/20 0.40
CYP2A6 P11509 1/20 0.39
POLB P06746 2/20 0.37
TSHR P16473 1/20 0.36
ERN1 O75460 1/20 0.35
GABRA1 P14867 1/20 0.34
GABRB2 P47870 1/20 0.34
HMGCR P04035 1/20 0.34
EPHX2 P34913 1/20 0.33
NR1H4 Q96RI1 1/20 0.33
SRC P12931 1/20 0.32
HTR1D P28221 1/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
ALDH1A1 P00352 1/20 0.32
CA2 P00918 1/20 0.32
TYR P14679 1/20 0.32
PGK1 P00558 1/20 0.31
PGK2 P07205 1/20 0.31
CYP1A2 P05177 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL189788 0.86 GABRA1 (0.46) RXRARXRBCYP2A6POLBGABRA1
SCHEMBL14005550 0.86 GABRA1 (0.40) RXRARXRBCYP2A6POLBTSHR
SCHEMBL15459309 0.83 ERN1 (0.38) RXRARXRBCYP2A6POLBERN1
SCHEMBL16348860 0.82 CYP2A6 (0.42) RXRARXRBCYP2A6EPHX2NR1H4
SCHEMBL2474610 0.81 NFE2L2 (0.41) CYP2A6ERN1PGK1PGK2MAPT
SCHEMBL8011119 0.80 GABBR2 (0.51) RXRARXRBPOLBTSHRGABRA1
SCHEMBL8011123 0.80 GABBR2 (0.51) RXRARXRBPOLBTSHRGABRA1
SCHEMBL12944940 0.79 CYP2A6 (0.33) CYP2A6ERN1
SCHEMBL3201259 0.78 GABRA1 (0.39) RXRARXRBCYP2A6POLBGABRA1
SCHEMBL3264978 0.78 GABRA1 (0.39) RXRARXRBCYP2A6POLBGABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023019094-A1 MONOACYLGLYCEROL LIPASE MODULATORS FOR USE IN AUTISM SPECTRUM DISORDERS JANSSEN PHARMACEUTICA NV (BE) 2023-02-16 WO disclosed
WO-2021160602-A1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2021-08-19 WO disclosed
US-20170312363-A1 MULTIFUNCTIONALIZED POLYETHYLENE GLYCOL DERIVATIVE AND PREPARATION METHOD THEREFOR XIAMEN SINOPEG BIOTECH CO., LTD. (CN) 2017-11-02 US disclosed
US-8716226-B2 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists SAINT LOUIS UNIVERSITY (US) 2014-05-06 US disclosed
US-20140051715-A1 3,5 Phenyl-Substituted Beta Amino Acid Derivatives as Integrin Antagonists SAINT LOUIS UNIVERSITY (US) 2014-02-20 US disclosed
US-6103688-A TERT-BUTYL SUBSTITUTED INDAN DERIVATIVES FIRMENICH SA (CH) 2000-08-15 US disclosed
EP-0685444-B1 Aromatic compounds and their use in perfumery FIRMENICH & CIE (CH) 2000-04-05 EP disclosed
US-5552379-A FLORAL, FOR COSMETICS AND HOUSEHOLD ITEMS FIRMENICH SA (CH) 1996-09-03 US disclosed
EP-0685444-A1 Aromatic compounds and their use in perfumery FIRMENICH SA (CH) 1995-12-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140051715-A1 3,5 Phenyl-Substituted Beta Amino Acid Derivatives as Integrin Antagonists ITGB3, ITGB5, ITGA5 RXRA 260/4885RXRB 200/4885CYP2A6 3386/4885
US-20170312363-A1 MULTIFUNCTIONALIZED POLYETHYLENE GLYCOL DERIVATIVE AND PREPARATION METHOD THEREFOR HDGF, F11, F12 RXRA 4327/4885RXRB 4355/4885CYP2A6 3508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.